{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T17:49:37Z","timestamp":1778262577945,"version":"3.51.4"},"reference-count":107,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice &amp; Research Clinical Rheumatology"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.berh.2023.101843","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T09:20:07Z","timestamp":1687425607000},"page":"101843","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Steroid sparing in vasculitis: Myth or reality?"],"prefix":"10.1016","volume":"37","author":[{"given":"Jennifer S.","family":"Hanberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eli M.","family":"Miloslavsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.berh.2023.101843_bib1","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.3389\/fimmu.2019.01545","article-title":"A\u00a0general introduction to glucocorticoid Biology","volume":"10","author":"Timmermans","year":"2019","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41584-020-0371-y","article-title":"Therapeutic glucocorticoids: mechanisms of actions in rheumatic diseases","volume":"16","author":"Hardy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101843_bib3","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1056\/NEJM197908023010503","article-title":"Cyclophosphamide therapy of severe systemic necrotizing vasculitis","volume":"301","author":"Fauci","year":"1979","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib4","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.rdc.2015.08.010","article-title":"Corticosteroids in antineutrophil cytoplasmic antibody-associated vasculitis","volume":"42","author":"Keller","year":"2016","journal-title":"Rheum Dis Clin N Am"},{"issue":"6","key":"10.1016\/j.berh.2023.101843_bib5","first-page":"360","article-title":"Complications of corticosteroid therapy: a Comprehensive literature review","volume":"38","author":"Koshi","year":"2022","journal-title":"J\u00a0Pharm Technol"},{"issue":"11","key":"10.1016\/j.berh.2023.101843_bib6","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1016\/j.clinthera.2017.09.011","article-title":"Long-term systemic corticosteroid exposure: a systematic literature review","volume":"39","author":"Rice","year":"2017","journal-title":"Clin Therapeut"},{"issue":"2","key":"10.1016\/j.berh.2023.101843_bib7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0b013e3282f51031","article-title":"The epidemiology of glucocorticoid-associated adverse events","volume":"20","author":"McDonough","year":"2008","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101843_bib8","doi-asserted-by":"crossref","first-page":"325","DOI":"10.7326\/M20-0432","article-title":"Association between oral corticosteroid bursts and severe adverse events : a Nationwide population-based cohort study","volume":"173","author":"Yao","year":"2020","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.1016\/j.berh.2023.101843_bib9","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1001\/jamapediatrics.2021.0433","article-title":"Association of oral corticosteroid bursts with severe adverse events in Children","volume":"175","author":"Yao","year":"2021","journal-title":"JAMA Pediatr"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib10","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.semarthrit.2015.07.009","article-title":"Improved survival in granulomatosis with polyangiitis: a general population-based study","volume":"45","author":"Wallace","year":"2016","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib11","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1136\/annrheumdis-2016-210942","article-title":"Mortality in ANCA-associated vasculitis: ameta-analysis of observational studies","volume":"76","author":"Tan","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1136\/ard.2010.137778","article-title":"Long-term patient survival in ANCA-associated vasculitis","volume":"70","author":"Flossmann","year":"2011","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.berh.2023.101843_bib13","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1056\/NEJMoa2023386","article-title":"Avacopan for the treatment of ANCA-associated vasculitis","volume":"384","author":"Jayne","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib14","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.ekir.2021.11.036","article-title":"Compassionate Use of avacopan in difficult-to-treat antineutrophil cytoplasmic antibody-associated vasculitis","volume":"7","author":"van Leeuwen","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib15","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12882-019-1226-0","article-title":"Intravenous pulse methylprednisolone for induction of remission in severe ANCA associated Vasculitis: a multi-center retrospective cohort study","volume":"20","author":"Chanouzas","year":"2019","journal-title":"BMC Nephrol"},{"issue":"8","key":"10.1016\/j.berh.2023.101843_bib16","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.41773","article-title":"2021 American College of Rheumatology\/vasculitis Foundation guideline for the management of antineutrophil cytoplasmic antibody-associated vasculitis","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib17","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1136\/annrheumdis-2016-209133","article-title":"EULAR\/ERA-EDTA recommendations for the management of ANCA-associated vasculitis","volume":"75","author":"Yates","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib18","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa0909905","article-title":"Rituximab versus cyclophosphamide for ANCA-associated vasculitis","volume":"363","author":"Stone","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.berh.2023.101843_bib19","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1093\/rheumatology\/kez001","article-title":"A\u00a0novel glucocorticoid-free maintenance regimen for anti-neutrophil cytoplasm antibody-associated vasculitis","volume":"58","author":"Pepper","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"2","key":"10.1016\/j.berh.2023.101843_bib20","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.ekir.2017.11.004","article-title":"Combination therapy with rituximab and cyclophosphamide for remission induction in ANCA vasculitis","volume":"3","author":"Cortazar","year":"2018","journal-title":"Kidney Int Rep"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2022-061339","article-title":"ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial","volume":"12","author":"Dirikgil","year":"2022","journal-title":"BMJ Open"},{"issue":"7","key":"10.1016\/j.berh.2023.101843_bib22","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1056\/NEJMoa1803537","article-title":"Plasma exchange and glucocorticoids in severe ANCA-associated vasculitis","volume":"382","author":"Walsh","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"21","key":"10.1016\/j.berh.2023.101843_bib23","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1001\/jama.2021.6615","article-title":"Effect of reduced-dose vs high-dose glucocorticoids added to rituximab on remission induction in ANCA-associated vasculitis: a randomized clinical trial","volume":"325","author":"Furuta","year":"2021","journal-title":"JAMA, J Am Med Assoc"},{"issue":"2","key":"10.1016\/j.berh.2023.101843_bib24","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-050507","article-title":"Comparative efficacy and safety of alternative glucocorticoids regimens in patients with ANCA-associated vasculitis: a systematic review","volume":"12","author":"Xiao","year":"2022","journal-title":"BMJ Open"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1136\/annrheumdis-2019-215672","article-title":"2018 Update of the EULAR recommendations for the management of large vessel vasculitis","volume":"79","author":"Hellmich","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2023.101843_bib26","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1002\/art.41774","article-title":"2021 American College of Rheumatology\/vasculitis Foundation guideline for the management of giant cell arteritis and Takayasu arteritis","volume":"73","author":"Maz","year":"2021","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101843_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.7326\/0003-4819-82-5-613","article-title":"Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study","volume":"82","author":"Hunder","year":"1975","journal-title":"Ann Intern Med"},{"issue":"10","key":"10.1016\/j.berh.2023.101843_bib28","doi-asserted-by":"crossref","first-page":"3310","DOI":"10.1002\/art.22163","article-title":"Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial","volume":"54","author":"Mazlumzadeh","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib29","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1136\/ard.47.9.733","article-title":"Polymyalgia rheumatica and temporal arteritis: a retrospective analysis of prognostic features and different corticosteroid regimens (11 year survey of 210 patients)","volume":"47","author":"Delecoeuillerie","year":"1988","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib30","first-page":"303","article-title":"Efficacy and adverse effects of different corticosteroid dose regimens in temporal arteritis: a retrospective study","volume":"15","author":"Nesher","year":"1997","journal-title":"Clin Exp Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib31","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1136\/bjo.85.9.1061","article-title":"Steroid management in giant cell arteritis","volume":"85","author":"Chan","year":"2001","journal-title":"Br J Ophthalmol"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib32","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1034\/j.1600-0420.2002.800403.x","article-title":"Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature","volume":"80","author":"Hayreh","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"issue":"6","key":"10.1016\/j.berh.2023.101843_bib33","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1007\/s11926-010-0135-9","article-title":"Giant cell arteritis: epidemiology, diagnosis, and management","volume":"12","author":"Gonzalez-Gay","year":"2010","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"10.1016\/j.berh.2023.101843_bib34","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/art.11388","article-title":"Glucocorticoid therapy in giant cell arteritis: duration and adverse outcomes","volume":"49","author":"Proven","year":"2003","journal-title":"Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.berh.2023.101843_bib35","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1136\/ard.48.8.658","article-title":"Treatment of polymyalgia rheumatica and giant cell arteritis. I. Steroid regimens in the first two months","volume":"48","author":"Kyle","year":"1989","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.berh.2023.101843_bib36","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1002\/art.40876","article-title":"Glucocorticoid dosages and acute-phase Reactant levels at giant cell arteritis flare in a randomized trial of tocilizumab","volume":"71","author":"Stone","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib37","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/acr.22429","article-title":"Incidence of giant cell arteritis and characteristics of patients: data-driven analysis of comorbidities","volume":"67","author":"Petri","year":"2015","journal-title":"Arthritis Care Res"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib38","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1613849","article-title":"Trial of tocilizumab in giant-cell arteritis","volume":"377","author":"Stone","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 124(2)","key":"10.1016\/j.berh.2023.101843_bib39","first-page":"112","article-title":"Tocilizumab in giant cell arteritis: differences between the GiACTA trial and a multicentre series of patients from the clinical practice","volume":"38","author":"Calderon-Goercke","year":"2020","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.berh.2023.101843_bib40","first-page":"123","article-title":"Tocilizumab in combination with 8 weeks of prednisone for giant cell arteritis","volume":"81","author":"Unizony","year":"2022","journal-title":"Eular Abstract"},{"key":"10.1016\/j.berh.2023.101843_bib41","first-page":"74","article-title":"Long-term efficacy of tocilizumab monotherapy after Ultra-short glucocorticoid administration to treat giant cell arteritis \u2013 one year follow-up of the GUSTO trial [abstract]","author":"Christ","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.berh.2023.101843_bib42","first-page":"80","article-title":"OP0061 a proof-of-concept study to assess the efficacy of tocilizumab monotherapy after ultra-short glucocorticoid administration to treat giant cell arteritis - the GUSTO trial [abstract]","author":"Christ","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.berh.2023.101843_bib43","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1136\/annrheumdis-2021-220347","article-title":"Treatment failure in giant cell arteritis","volume":"80","author":"Unizony","year":"2021","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib44","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/j.semarthrit.2020.04.012","article-title":"Patterns of clinical presentation in Takayasu's arteritis","volume":"50","author":"Quinn","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib45","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1136\/annrheumdis-2017-211878","article-title":"Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study)","volume":"77","author":"Nakaoka","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.berh.2023.101843_bib46","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1007\/s10067-013-2380-6","article-title":"Tumor necrosis factor alpha inhibitors in patients with Takayasu's arteritis refractory to standard immunosuppressive treatment: cases series and review of the literature","volume":"32","author":"Novikov","year":"2013","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13075-017-1316-y","article-title":"TNF inhibitors appear to inhibit disease progression and improve outcome in Takayasu arteritis; an observational, population-based time trend study","volume":"19","author":"Gudbrandsson","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.berh.2023.101843_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320975233","article-title":"Effectiveness and safety of methotrexate versus leflunomide in 12-month treatment for Takayasu arteritis","volume":"11","author":"Wu","year":"2020","journal-title":"Ther Adv Chronic Dis"},{"issue":"6","key":"10.1016\/j.berh.2023.101843_bib49","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1136\/annrheumdis-2012-201531","article-title":"A\u00a0vasculitis centre based management strategy leads to improved outcome in eosinophilic granulomatosis and polyangiitis (Churg-Strauss, EGPA): monocentric experiences in 150 patients","volume":"72","author":"Moosig","year":"2013","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib50","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/art.37721","article-title":"Eosinophilic granulomatosis with polyangiitis (Churg-Strauss): clinical characteristics and long-term followup of the 383 patients enrolled in the French Vasculitis Study Group cohort","volume":"65","author":"Comarmond","year":"2013","journal-title":"Arthritis Rheum"},{"issue":"20","key":"10.1016\/j.berh.2023.101843_bib51","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.berh.2023.101843_bib52","unstructured":"Paris AP-Hd, Group FVS, Cochin U-CPDN. Study of mepolizumab-based regimen compared to Conventional therapeutic strategy in patients with eosinophilic granulomatosis with polyangiitis (E-merge). ClinicalTrialsgov identifier: NCT05030155."},{"key":"10.1016\/j.berh.2023.101843_bib53","unstructured":"GlaxoSmithKline. Efficacy and safety of depemokimab compared with mepolizumab in adults with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA) (OCEAN). ClinicalTrialsgov Identifier: NCT05263934."},{"issue":"11","key":"10.1016\/j.berh.2023.101843_bib54","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1002\/art.40205","article-title":"Adding azathioprine to remission-induction glucocorticoids for eosinophilic granulomatosis with polyangiitis (Churg-Strauss), microscopic polyangiitis, or polyarteritis nodosa without poor prognosis factors: a randomized, controlled trial","volume":"69","author":"Puechal","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.berh.2023.101843_bib55","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1186\/s13023-020-01621-3","article-title":"French recommendations for the management of systemic necrotizing vasculitides (polyarteritis nodosa and ANCA-associated vasculitides)","volume":"15","author":"Terrier","year":"2020","journal-title":"Orphanet J Rare Dis"},{"issue":"8","key":"10.1016\/j.berh.2023.101843_bib56","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/acr.24633","article-title":"2021 American College of Rheumatology\/vasculitis Foundation guideline for the management of polyarteritis nodosa","volume":"73","author":"Chung","year":"2021","journal-title":"Arthritis Care Res"},{"key":"10.1016\/j.berh.2023.101843_bib57","doi-asserted-by":"crossref","DOI":"10.1155\/2009\/738293","article-title":"Rituximab efficacy during a refractory polyarteritis nodosa flare","volume":"2009","author":"Ribeiro","year":"2009","journal-title":"Case Rep Med"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib58","doi-asserted-by":"crossref","first-page":"696","DOI":"10.3109\/14397595.2015.1014153","article-title":"A\u00a0case of refractory polyarteritis nodosa successfully treated with rituximab","volume":"27","author":"Seri","year":"2017","journal-title":"Mod Rheumatol"},{"issue":"10","key":"10.1016\/j.berh.2023.101843_bib59","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1007\/s10067-019-04474-9","article-title":"Infliximab for the treatment of refractory polyarteritis nodosa","volume":"38","author":"Ginsberg","year":"2019","journal-title":"Clin Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2023.101843_bib60","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.2169\/internalmedicine.56.8235","article-title":"The successful treatment of refractory polyarteritis nodosa using infliximab","volume":"56","author":"Matsuo","year":"2017","journal-title":"Intern Med"},{"issue":"2","key":"10.1016\/j.berh.2023.101843_bib61","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s00296-018-4210-2","article-title":"Tocilizumab treatment in refractory polyarteritis nodosa: a case report and review of the literature","volume":"39","author":"Krusche","year":"2019","journal-title":"Rheumatol Int"},{"issue":"10","key":"10.1016\/j.berh.2023.101843_bib62","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.1093\/rheumatology\/keaa079","article-title":"Tocilizumab treatment for polyarteritis nodosa","volume":"59","author":"Krusche","year":"2020","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"10.1016\/j.berh.2023.101843_bib63","first-page":"560","article-title":"Tocilizumab treatment in polyarteritis nodosa","volume":"21","author":"Bodoki","year":"2019","journal-title":"Isr Med Assoc J"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib64","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.1002\/art.27340","article-title":"Treatment of polyarteritis nodosa and microscopic polyangiitis without poor-prognosis factors: a prospective randomized study of one hundred twenty-four patients","volume":"62","author":"Ribi","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib65","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11926-021-00983-2","article-title":"Clinical approach to diagnosis and therapy of polyarteritis nodosa","volume":"23","author":"Hocevar","year":"2021","journal-title":"Curr Rheumatol Rep"},{"issue":"10","key":"10.1016\/j.berh.2023.101843_bib66","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2020-218710","article-title":"Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on 'Tofacitinib for polyarteritis nodosa: a tailored therapy' by Rimar et\u00a0al","volume":"81","author":"Akiyama","year":"2022","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.berh.2023.101843_bib67","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/0002-9343(79)90634-X","article-title":"Immunosuppressive and corticosteroid therapy of polyarteritis nodosa","volume":"67","author":"Leib","year":"1979","journal-title":"Am J Med"},{"issue":"5","key":"10.1016\/j.berh.2023.101843_bib68","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jaad.2021.06.872","article-title":"Efficacy and safety of treatments in cutaneous polyarteritis nodosa: a French observational retrospective study","volume":"86","author":"Bettuzzi","year":"2022","journal-title":"J\u00a0Am Acad Dermatol"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib69","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1093\/rheumatology\/keab402","article-title":"Therapeutic options for cutaneous polyarteritis nodosa: a systematic review","volume":"60","author":"Papachristodoulou","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"6","key":"10.1016\/j.berh.2023.101843_bib70","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1136\/annrheumdis-2018-213225","article-title":"2018 Update of the EULAR recommendations for the management of Behcet's syndrome","volume":"77","author":"Hatemi","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib71","first-page":"98","article-title":"Short-term trial of etanercept in Behcet's disease: a double blind, placebo controlled study","volume":"32","author":"Melikoglu","year":"2005","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.berh.2023.101843_bib72","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3109\/s10165-009-0200-2","article-title":"Colchicine versus placebo in Behcet's disease: randomized, double-blind, controlled crossover trial","volume":"19","author":"Davatchi","year":"2009","journal-title":"Mod Rheumatol"},{"issue":"11","key":"10.1016\/j.berh.2023.101843_bib73","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1002\/1529-0131(200111)44:11<2686::AID-ART448>3.0.CO;2-H","article-title":"A\u00a0double-blind trial of colchicine in Behcet's syndrome","volume":"44","author":"Yurdakul","year":"2001","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib74","first-page":"399","article-title":"A\u00a0double blind study of colchicine in Behcet's disease","volume":"65","author":"Aktulga","year":"1980","journal-title":"Haematologica"},{"issue":"20","key":"10.1016\/j.berh.2023.101843_bib75","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1056\/NEJMoa1816594","article-title":"Trial of apremilast for oral ulcers in Behcet's syndrome","volume":"381","author":"Hatemi","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"Suppl 121(6)","key":"10.1016\/j.berh.2023.101843_bib76","first-page":"137","article-title":"Induction of ocular Behcet's disease remission after short-term treatment with infliximab: a case series of 11 patients with a follow-up from 4 to 16 years","volume":"37","author":"Sfikakis","year":"2019","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib77","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s10792-006-9006-9","article-title":"Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behcet's disease","volume":"26","author":"Abu El-Asrar","year":"2005","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.berh.2023.101843_bib78","doi-asserted-by":"crossref","DOI":"10.1177\/17562848221116666","article-title":"Anti-TNF-alpha agents for refractory intestinal Behcet's disease: case series and meta-analysis","volume":"15","author":"Zhan","year":"2022","journal-title":"Ther Adv Gastroenterol"},{"issue":"8647","key":"10.1016\/j.berh.2023.101843_bib79","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/S0140-6736(89)92381-7","article-title":"Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease","volume":"1","author":"Masuda","year":"1989","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.berh.2023.101843_bib80","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/acr.20176","article-title":"Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis","volume":"62","author":"Walsh","year":"2010","journal-title":"Arthritis Care Res"},{"issue":"2","key":"10.1016\/j.berh.2023.101843_bib81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1097\/MD.0000000000000020","article-title":"Granulomatosis with polyangiitis (Wegener's): impact of maintenance therapy duration","volume":"93","author":"Springer","year":"2014","journal-title":"Medicine (Baltim)"},{"issue":"10","key":"10.1016\/j.berh.2023.101843_bib82","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1136\/annrheumdis-2017-211123","article-title":"Randomised controlled trial of prolonged treatment in the remission phase of ANCA-associated vasculitis","volume":"76","author":"Karras","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib83","doi-asserted-by":"crossref","first-page":"179","DOI":"10.7326\/M19-3827","article-title":"Long-term rituximab Use to maintain remission of antineutrophil cytoplasmic antibody-associated vasculitis: a randomized trial","volume":"173","author":"Charles","year":"2020","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.1016\/j.berh.2023.101843_bib84","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S2665-9913(21)00038-2","article-title":"Long-term effect of tocilizumab in patients with giant cell arteritis: open-label extension phase of the Giant Cell Arteritis Actemra (GiACTA) trial","volume":"3","author":"Stone","year":"2021","journal-title":"Lancet Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib85","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1093\/rheumatology\/kez091","article-title":"Risk of relapse after discontinuation of tocilizumab therapy in giant cell arteritis","volume":"58","author":"Adler","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib86","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3899\/jrheum.200952","article-title":"Real-world risk of relapse of giant cell arteritis treated with tocilizumab: a retrospective analysis of 43 patients","volume":"48","author":"Clement","year":"2021","journal-title":"J\u00a0Rheumatol"},{"key":"10.1016\/j.berh.2023.101843_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2023.152174","article-title":"Effectiveness of a two-year tapered course of tocilizumab in patients with giant cell arteritis: a single-centre prospective study","volume":"59","author":"Tomelleri","year":"2023","journal-title":"Semin Arthritis Rheum"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib88","first-page":"829","article-title":"Optimisation of tocilizumab therapy in giant cell arteritis. A multicentre real-life study of 471 patients","volume":"41","author":"Calderon-Goercke","year":"2023","journal-title":"Clin Exp Rheumatol"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib89","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.tem.2017.10.010","article-title":"Therapeutic mechanisms of glucocorticoids","volume":"29","author":"Vandewalle","year":"2018","journal-title":"Trends Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.berh.2023.101843_bib90","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188810","article-title":"Efficacy and safety of selective glucocorticoid receptor modulators in comparison to glucocorticoids in arthritis, a systematic review","volume":"12","author":"Safy","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.berh.2023.101843_bib91","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1093\/rheumatology\/key169","article-title":"The 70th anniversary of glucocorticoids in rheumatic diseases: the second youth of an old friend","volume":"58","author":"Palmowski","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.berh.2023.101843_bib92","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11926-020-00961-0","article-title":"Reducing the toxicity of long-term glucocorticoid treatment in large vessel vasculitis","volume":"22","author":"Palmowski","year":"2020","journal-title":"Curr Rheumatol Rep"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib93","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2018-000889","article-title":"Fosdagrocorat (PF-04171327) versus prednisone or placebo in rheumatoid arthritis: a randomised, double-blind, multicentre, phase IIb study","volume":"5","author":"Buttgereit","year":"2019","journal-title":"RMD Open"},{"issue":"6","key":"10.1016\/j.berh.2023.101843_bib94","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/art.42415","volume":"75","author":"Buttgereit","year":"2023","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.berh.2023.101843_bib95","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41574-022-00683-6","article-title":"Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions","volume":"18","author":"Li","year":"2022","journal-title":"Nat Rev Endocrinol"},{"issue":"6","key":"10.1016\/j.berh.2023.101843_bib96","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.34067\/KID.0000502021","article-title":"Glucocorticoid therapy in ANCA vasculitis: using the glucocorticoid toxicity index as an outcome measure","volume":"2","author":"Floyd","year":"2021","journal-title":"Kidney360"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib97","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1136\/annrheumdis-2016-210002","article-title":"Development of a Glucocorticoid Toxicity Index (GTI) using multicriteria decision analysis","volume":"76","author":"Miloslavsky","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.berh.2023.101843_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2022.152010","article-title":"The glucocorticoid toxicity index: measuring change in glucocorticoid toxicity over time","volume":"55","author":"Stone","year":"2022","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.berh.2023.101843_bib99","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s40744-018-0112-8","article-title":"Risk associated with Cumulative oral glucocorticoid Use in patients with giant cell arteritis in real-world databases from the USA and UK","volume":"5","author":"Gale","year":"2018","journal-title":"Rheumatol Ther"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib100","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13075-020-02171-6","article-title":"Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions","volume":"22","author":"Sugihara","year":"2020","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbspin.2022.105494","article-title":"Epidemiology and predictors of relapse in giant cell arteritis: a systematic review and meta-analysis","volume":"90","author":"Moreel","year":"2022","journal-title":"Joint Bone Spine"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib102","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3899\/jrheum.181127","article-title":"Factors associated with relapse and dependence on glucocorticoids in giant cell arteritis","volume":"47","author":"Dumont","year":"2020","journal-title":"J\u00a0Rheumatol"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib103","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/rheumatology\/keaa667","article-title":"Prevalence and risk factors of relapse in patients with ANCA-associated vasculitis receiving cyclophosphamide induction: a systematic review and meta-analysis of large observational studies","volume":"60","author":"He","year":"2021","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib104","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ekir.2019.10.005","article-title":"Relapse in anti-neutrophil cytoplasm antibody (ANCA)-Associated vasculitis","volume":"5","author":"Salama","year":"2020","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1016\/j.berh.2023.101843_bib105","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243572","article-title":"Association between sinusitis and relapse and changes in the myeloperoxidase-antineutrophil cytoplasmic antibody in microscopic polyangiitis","volume":"15","author":"Tanaka","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.berh.2023.101843_bib106","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13075-021-02471-5","article-title":"Usefulness of tissue inhibitor of metalloproteinase 1 as a predictor of sustained remission in patients with antineutrophil cytoplasmic antibody-associated vasculitis","volume":"23","author":"Ishizaki","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"10.1016\/j.berh.2023.101843_bib107","doi-asserted-by":"crossref","first-page":"445","DOI":"10.46497\/ArchRheumatol.2021.8687","article-title":"Predictors of renal and patient outcomes in anti-neutrophil cytoplasmic antibody-associated vasculitis: our single-center, tertiary care experience","volume":"36","author":"Toraman","year":"2021","journal-title":"Arch Rheumatol"}],"container-title":["Best Practice &amp; Research Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000293?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521694223000293?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:23:50Z","timestamp":1761499430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521694223000293"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":107,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["S1521694223000293"],"URL":"https:\/\/doi.org\/10.1016\/j.berh.2023.101843","relation":{},"ISSN":["1521-6942"],"issn-type":[{"value":"1521-6942","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Steroid sparing in vasculitis: Myth or reality?","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Rheumatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.berh.2023.101843","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101843"}}